Physician profile
Stephen Ray Timms
NPI 1922009380
$3,544.05
in general payments reported to CMS, 2019-2025
30 companies · $93.21 in 2025
The $93.21 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,943 · 2020: $481 · 2021: $119 · 2022: $417 · 2023: $354 · 2024: $137 · 2025: $93.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.14 |
| Education | $123.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $698.74 | 2019-2024 | Briviact |
| Teva Pharmaceuticals USA, INC. | $494.67 | 2019-2024 | |
| Biogen, INC. | $313.01 | 2019-2022 | |
| Lilly USA, LLC | $249.28 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $219.51 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $159.20 | 2019-2020 | |
| Genzyme Corporation | $149.15 | 2019 | |
| Allergan, INC. | $126.20 | 2020 | |
| Sunovion Pharmaceuticals INC. | $104.60 | 2019 | |
| Livanova USA, INC. | $96.81 | 2019 | |
| Argenx US, INC. | $88.72 | 2023 | Vyvgart, Vyvgart Hytrulo |
| Acadia Pharmaceuticals INC | $82.24 | 2019-2021 | |
| Amgen INC. | $81.25 | 2019-2020 | |
| Horizon Therapeutics Plc | $67.96 | 2023 | Uplizna |
| Emd Serono, INC. | $67.24 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $63.25 | 2025 | |
| Sumitomo Pharma America, INC. | $61.40 | 2023 | Aptiom |
| Amneal Pharmaceuticals LLC | $55.18 | 2019 | |
| Lundbeck LLC | $53.87 | 2021-2023 | Vyepti |
| Tanabe Pharma America, INC. | $44.50 | 2019-2020 | |
| Mdd US Operations, LLC | $41.74 | 2019 | |
| Acorda Therapeutics, INC | $41.26 | 2019 | |
| Avanir Pharmaceuticals, INC. | $37.09 | 2019 | |
| Neurelis, INC. | $29.96 | 2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $26.43 | 2019 | |
| Pfizer INC. | $23.94 | 2024 | |
| Csl Behring | $20.42 | 2019 | |
| Abbott Laboratories | $17.75 | 2019 | |
| Sk Life Science, INC. | $16.03 | 2020 | |
| Genentech USA, INC. | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Timms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.